AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 42 min read$ALKS

Gaffin David Joseph sold $88K of ALKS

Gaffin David Joseph (EVP, CLO, Alkermes, Inc.) sold 2,034 shares of Alkermes plc. (ALKS) at $43.05 on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Gaffin David Joseph
Published Jun 4, 2026, 9:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 4, 2026, 9:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ALKS
Neutral
medium confidence
Mentioned
$ALKS
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALKSNeutralLow
01

Why it matters

This disclosure mainly informs positioning/sentiment rather than changing Alkermes’ fundamentals.

02

Market read

A modest sentiment datapoint for ALKS, but unlikely to drive a durable repricing without additional company-specific catalysts.

03

What to watch

The filing does not indicate intent or new information about Alkermes fundamentals; traders should avoid extrapolating from a single small sale without corroborating catalysts.

Relevance 6/10Novelty 6/10Timing: Filed after-hours on 2026-06-04 (SEC Form 4 at 17:00 ET).

Background

SEC Form 4 reports insider transactions by company officers/directors/10% owners; 10b5-1 plans are pre-scheduled trades intended to reduce timing-based inference.

Company-level read

Ticker impact

$ALKSNeutralMedium confidence
Context

Alkermes disclosed an officer open-market sale of 2,034 shares (~$87.6K) under a pre-arranged 10b5-1 plan on 2026-06-04.

Expected impact

Low likelihood of a sustained price move; any reaction is likely brief unless accompanied by other news.

Evidence & confidence

The filing is an ownership-change disclosure (not earnings/M&A/regulatory/drug data). The sale is explicitly under a pre-arranged 10b5-1 plan, which reduces interpretive signal.

Market effects

Sector

Minimal; this is company-specific insider activity with no stated operational/clinical/regulatory change.

Regional

None indicated beyond potential small sentiment effect in US biotech/biopharma trading.

Global

None indicated.

Counterpoint

What could challenge this read

Because the transaction is under a 10b5-1 plan, the market may overreact; price impact could be negligible once traders recognize the pre-arranged nature.

Key entities

  • issuer
    Alkermes plc

    Subject of the Form 4 insider transaction; EVP sold shares under a 10b5-1 plan.

  • insider
    Gaffin David Joseph

    EVP, CLO at Alkermes; executed an open-market sale of 2,034 shares.

Read at source← All news

Related articles

JUL 30
$ALKSMed

Alkermes plc Q2 2026 Earnings Call Summary

Strategic Evolution and Operational Context Management characterized the current period as a major phase of growth, with the orexin platform evolving from a hypersomnolence focus to a broad neurocircuitry platform for ADHD and fatigue. Alixorexton is positioned as a leading asset, being the only orexin 2 receptor agonist to demonstrate efficacy and tolerability across both NT1 and NT2 in large Phase 2 studies.

yahoo.com6 min
JUL 28
$ALKSMedAI 8/10

Alkermes plc. (ALKS): Results of Operations and Financial Condition

Alkermes plc. (ALKS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 alks-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports Second Quarter 2026 Financial Results — Second Quarter Revenues of $496.0 Million — — GAAP Net Income

SEC EDGAR 8-K6 min
JUL 25
$ALKSMed

Interim Analysis: Sustained Wakefulness with Alixorexton in Narcolepsy

Alkermes plc reported interim results from a long-term extension study of alixorexton in adults with narcolepsy type 1 and type 2. At week 24, alixorexton showed sustained improvements on the Maintenance of Wakefulness Test and Epworth Sleepiness Scale, with mean MWT sleep latency about 29 minutes (NT1) and 18 minutes (NT2) and mean ESS about 7.5 (NT1) and 8.9 (NT2). No serious treatment-emergent adverse events were reported.

sleepreviewmag.com5 min
JUL 23
$ALKSMed

First MS Mobility Drug Gets Green Light From NHS England

NHS England said it will make fampridine (Fampyra), a pill for adults with multiple sclerosis-related walking impairment, routinely available on the NHS after a Clinical Priorities Advisory Group review. NHSE cited trials showing improved walking speed in 43% of patients and about a 25% speed increase, with ~5,000 eligible patients in England in year one. The decision follows a 2022 NICE cost-effectiveness refusal and the expiry of the Fampyra brand patent.

medscape.com4 min